A novel drug combination, improvements in quality of life, and breakthrough hemolysis control are among the clinical highlights in paroxysmal nocturnal hemoglobinuria (PNH) presented at the 2024 ...
The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback